We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OBT and Boehringer Ingelheim Enter Collaboration
News

OBT and Boehringer Ingelheim Enter Collaboration

OBT and Boehringer Ingelheim Enter Collaboration
News

OBT and Boehringer Ingelheim Enter Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OBT and Boehringer Ingelheim Enter Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) have announced a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications.

Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.

Christian Rohlff, CEO of OBT, commented: “Selecting the right target is fundamental for the successful development of a first-in-class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development.”

Advertisement